Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH) Response from Indigenous Innovators Collaborative

种族

• 批准号: 10823600
• 负责人: Billie Kipp
• 金额: $ 50万
• 依托单位: AMERICANS FOR INDIAN OPPORTUNITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-05 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10823600
• 关键词: Racial; Ethnic; minority; Acceleration; Consortium

Project Summary/Abstract 30 lines of text With a collaborative approach grounded in Indigenous core cultural values, the Indigenous Innovators Collaborative (IIC) team will engage in community-based participatory research study to address the FDA priorities as outlined in FDA OMHHE Health Equity Innovation Award: Racial and Ethnic Minority Acceleration Consortium for Health Equity (REACH) funding opportunity. The IIC seeks to engage American Indian and Alaska Native (AIAN) communities, stakeholders, researchers in an exploration of clinical trials and promote cultural knowledge in understanding clinical trials in Indian Country. The IIC consists of core partners that form the Administrative Core (AC) of this project, including: (1) Americans for Indian Opportunity (AIO), which serves as the fiscal agent/grant administrator; (2) Co-Investigator 1: Dr. Myra Parker (Three Affiliated Tribes), University of Washington; (3) Co-Investigator 2: Dr. Billie Jo Kipp (Blackfeet), Natives in Philanthropy; (4) Principle Investigator: Stephine Poston (Pueblo of Sandia), Poston & Associates, LLC; and, (5) the United Tribes Technical College (UTTC), an accredited, land-grant tribal college located in Bismarck, North Dakota, that serves the five reservations in ND and tribal members across the U.S. UTTC has provided higher education support to over 10,000 AI students from over 75 tribes. We propose to expand this effort to implement an exploratory study that would employ a mixed methods approach to improve understandings of AIAN perceptions of clinical trials and gene therapy across multiple regions of the U.S. Our aims include: 1. Specific Aim 1 – Partner with local tribal colleges to assess AIAN community knowledge, concerns, and beliefs about clinical trials and gene therapy within the 12 IHS regions using a mixed methods approach. a. Hypothesis 1 – AIAN community knowledge, concerns, and beliefs about clinical trials and gene therapy will vary across IHS regions and will reflect local tribal cultural understandings. 2. Specific Aim 2 – Identify barriers and supports for clinical trials and gene therapy among AIAN within the 12 IHS regions by collecting qualitative data from AIAN providers, researchers, and public health experts. a. Hypothesis 2 – Barriers and supports for clinical trials and gene therapy among AIAN will vary by IHS Region and tribal cultures.

项目摘要/摘要30行文本 通过以土著核心文化价值观为基础的合作方法， 创新者合作（IIC）团队将参与基于社区的参与式研究 研究旨在解决FDA OMHHE健康公平创新奖中概述的FDA优先事项： 种族和少数民族健康公平加速联盟（REACH） 机会IIC寻求让美国印第安人和阿拉斯加原住民社区参与， 利益相关者，研究人员在临床试验的探索和促进文化知识， 了解印度的临床试验IIC由核心合作伙伴组成， 该项目的行政核心（AC），包括：（1）美国印第安人机会（AIO）， 担任财务代理人/赠款管理人;（2）共同研究者1：Myra帕克博士 （三个附属部落），华盛顿大学;（3）共同研究者2：Billie Jo Kipp博士 （黑脚），当地人在慈善事业;（4）主要调查员：斯蒂芬波斯顿（普韦布洛的 Sandia），Poston & Associates，LLC;以及（5）联合部落技术学院（UTTC）， 一个认可的，赠地部落学院位于俾斯麦，北达科他州，为五个 在ND和整个美国的部落成员保留UTTC提供高等教育 为来自75个部落的10，000多名AI学生提供支持。我们建议扩大这一努力， 进行一项探索性研究，采用混合方法， 了解AIAN对多个地区临床试验和基因治疗的看法 我们的目标包括： 1.具体目标1 -与当地部落学院合作，评估土著印第安人网络社区 12 IHS中关于临床试验和基因治疗的知识、关注点和信念 使用混合方法的区域。 a.假设1 - AIAN社区对临床的知识、关注和信念 试验和基因治疗将因IHS地区而异， 文化理解。 2.具体目标2 -确定临床试验和基因治疗的障碍和支持 通过收集AIAN的定性数据，在12个IHS区域内的AIAN之间进行 供应商、研究人员和公共卫生专家。 a.假设2 -临床试验和基因治疗的障碍和支持， AIAN将因IHS地区和部落文化而异。